Guzin Demirag

Guzin Demirag

Auto-generated profile, based on publicly available information

Guzin Demirag

Department of Medical Oncology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SYSuayib Yalcin
Suayib Yalcin
FDFaysal Dane
Faysal Dane
BOBerna Oksuzoglu
Berna Oksuzoglu
NONuriye Yildirim Ozdemir
Nuriye Yildirim Ozdemir
AIAbdurrahman Işıkdoğan
Abdurrahman Işıkdoğan
SKSaadettin Kilickap
Saadettin Kilickap
Background: Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in advanced pancreatic adenocarcinoma is unknown. Methods: A total of 125 patients were randomized to combination therapy (1000 mg/m2 gemcitabine + 125 mg/m2 nab-paclitaxel) and single-agent gemcitabine (1000 mg/m2) arms to take treatment weekly for 7 of 8 weeks, and following 3 of 4 weeks, until progression or severe toxicity. Primary endpoints were three-months of definitive deterioration free percent of patients, and QoL. Results: Overall QoL analyses showed that 34 and 58.3% of cases in gemcitabine and gemcitabine+nab-P arms had no deterioration in 3rd month QoL scores (p = 0.018). These proportions were 27.3 and 36.6% in 6th month assessments, respectively (p = 0.357). Median overall survivals in combination and single-agent arms were 9.92 months and 5.95 months, respectively (HR: 0.64, 95% CI: 0.42–0.86, p = 0.038). Median progression free survivals in these treatment arms were 6.28 and 3.22 months, respectively (HR: 0.58, 95% CI: 0.39–0.87, p = 0.008). Median time-to-deterioration were 5.36 vs 3.68 months, and objective response rates were 37.1% vs 23.7% (p = 0.009), respectively in combination and single-agent arms. Conclusions: Combination therapy with gemcitabine + nab-paclitaxel had better overall and progression-free survival than gemcitabine alone. Also, combination therapy showed increased response rate without toxicity or deteriorated QoL. Combination treatment with gemcitabine and nab-paclitaxel may provide significant benefit for advanced pancreatic cancer. Trial registration: This study has been registered in ClinicalTrials.gov as NCT03807999 on January 8, 2019 (retrospectively registered).

10 December 2022 in BMC Urology
Verified
Journal Article
Open access
PDF file
ODOzden Demir
Ozden Demir
GDGuzin Demirag
Guzin Demirag
GAGokhan Aslan
Gokhan Aslan
Of all the genitourinary cancers, renal cell carcinoma (RCC) is still the most common malignancy with high mortality rates. There are still insufficient biomarkers to predict disease prognosis. Systemic inflammation markers play an important role in tumor development and growth. There are studies which show the relationship of fibrinogen and albumin individually with cancer prognosis in many cancers. Fibrinogen/albumin ratio(FAR), on the other hand, has prognostic importance like other inflammation indicators in cancer. Therefore, we investigated whether FAR had a potential value in evaluating the prognosis of patients with nonmetastatic kidney cancer or not. A total of 72 patients who had nephrectomy operation at 19 Mayıs University, Faculty of Medicine between January 2019 and January 2021 and who did not have distant metastasis were included in the study. FAR was calculated from the blood taken from the patients before the nephrectomy operation. The cut-off value was found for this FAR by receiver operating characteristic(ROC) curve analysis. The patients were divided into 2 groups as high- and low-FAR according to this cut-off value. Kaplan Meier test was used to evaluate the predictive value of clinicopathological parameters for overall survival (OS). The Log-rank test was used to determine whether there was a relationship between the preoperative FAR and the clinico-pathological data of the patients. The best cutoff value for the FAR was 0.114. A FAR > 0.114 was associated with higher Fuhrman Grade (FG) (P < 0.0001) and later pathological T stage (P < 0.0001). Patients with a high FAR (> 0.114) had worse OS [Std. Error 2.932, 95% confidence interval (CI): 73.659–85.154, P < 0.0001]. In addition, a positive significant correlation was found between high grade and platelet lymphocyte ratio (p < 0,020). Furthermore, a significant correlation was found between the pathology t stage of the patients and the platelet lymphocyte ratio (p: 0.020). The preoperative FAR is an independent prognostic factor of OS in renal cancer patients. A FAR > 0.114 was significantly related to decreased survival in renal cancer patients. In addition, the platelet-lymphocyte ratio seems to be related to OS, as well as FAR. Further studies are required on this subject.

26 July 2024 in BMC Neurology
Verified
Journal Article
Open access
PDF file
ODOzden Demir
Ozden Demir
GDGuzin Demirag
Guzin Demirag
FCFurkan Cakmak
Furkan Cakmak
DBDemet Işık Bayraktar
Demet Işık Bayraktar
LTLeman Tomak
Leman Tomak
Background: We aimed to investigate whether the HALP score was a predictor of survival in patients with Glioblastoma (GBM). Methods: A total of 84 Glioblastoma (GBM) patients followed in our clinic were included in the study. HALP scores were calculated using the preoperative hemoglobin, albumin, lymphocyte and platelet results of the patients. For the HALP score, a cut-off value was found by examining the area below the receiver operating characteristic (ROC) curve. Patients were divided into two groups as low and high according to this cut-off value. The relationships among the clinical, dermographic and laboratory parameters of the patients were examined using these two groups. Results: Median OS, PFS, HALP score, NLR, PLR were 15 months (1.0–78.0), 8 months (1.0–66.0), 37.39 ± 23.84 (min 6.00-max 132.31), 4.14, 145.07 respectively. A statistically significant correlation was found between HALP score and OS, PFS, NLR, PLR, ECOG-PS status using Spearman’s rho test (p = 0.001, p < 0.001, p < 0.001, p < 0.001, p = 0.026 respectively). For the HALP score, a cut-off value of = 37.39 (AUC = 0.698, 95% CI, p < 0.002) was found using ROC analysis. Median OS was 12 (6.99–17.01) months in the low HALP group and 21 (11.37–30.63) months in the high HALP group (p = 0.117). NLR and PLR were significantly lower in the HALP high group (p < 0.001, p < 0.001 respectively). The ratio of receiving treatment was significantly higher in the high HALP group (p < 0.05). In Multivariate analysis, significant results were found for treatment status and ECOG-PS status (p < 0.001, p = 0.038 respectively). Conclusions: The HALP score measured at the beginning of treatment seems to have predictive importance in the prognosis of GBM patients. A HALP score of > 37.39 was associated with prolonged survival in high-grade brain tumors.

29 September 2022 in Journal of Business Research - Turk
Verified
Journal Article
Closed access
SDSibel Demirağ
Sibel Demirağ
MTMetehan Tolon
Metehan Tolon
Amaç –Günümüz hızla dünümüze dönüşürken teknoloji baş döndürücü hızını yeniliklerle desteklemektedir. Bu hız kurumların rekabet güçlerini sınarken rekabet sırasında olumlu ya da olumsuz oluşturdukları imajlarına da etki etmektedir. İmajlarını oluşturmada ilk adımları ise kurumsal kimlik öğeleri ile başlamaktadır. Seyircinin kurumla ilk etkileşim noktaları özellikle önem kazanmaktadır. Bu bağlamda çalışma amacı Ankara Devlet Opera ve Balesi kurumsal imaj ve kurumsal kimlik unsurlarının demografik özelliklerdeki farklılıklar göz önüne alınmak suretiyle seyirciler tarafından nasıl algılandığını tespit etmektir.Yöntem –Kurumsal imaj ve kurumsal kimlik öğelerinin nasıl algılandığını ölçmek amacıyla Ankara Devlet Opera ve Balesi hakkında fikre sahip olan veya temsil izlemiş kişiler arasından kolayda örneklem yöntemi kullanılarak veri toplanmıştır. Çevrimiçi platformda hazırlanan anket toplamda 630 kişi tarafından cevaplanmış ancak 403 kişi tarafından eksiksiz tamamlanmıştır. Anket 22.02.2020 ile 31.05.2021 tarihleri arasında yürütülmüştür. Veriler SPSS 26.0 programı ve SPSS Process 3.5 kullanılarak analiz edilmiştir. Bulgular –Analiz sonucu Ankara Devlet Opera ve Bale seyircisinin kurumsal kimlik öğeleri ile cinsiyet arasında anlamlı bir fark olduğu görülmüştür. Algılanan kurum imajı ile cinsiyet arasında da anlamlı bir fark gözlenmiştir. Kurumsal kimlik unsurları olan kurumsal görünüm, kurumsal iletişim ve kurumsal davranış ile algılanan kurum imajı arasında pozitif bir ilişki saptanmıştır. Kurumsal kimlik unsurları ile algılanan kurum imajı arasındaki ilişkide temsil izleme durumunun sadece kurumsal iletişim yönünden moderatör etkisi bulunduğu ortaya çıkmaktadır. Tartışma –Kurumsal imaj bir işletmeyi birçok yönden etkileyen bir unsurdur. Bu nedenle kurumsal kimlik öğeleri üzerinden kurumsal imajın pazarlanması oldukça önemlidir. Yapılan çalışmalar incelendiğinde özellikle devletin sanat kurumları hakkında çok az sayıda çalışma bulunduğu görülmektedir. Bu sebeple, bu araştırmanın literatüre katkı sağlaması ve gelecek çalışmalara yol göstermesi beklenmektedir.